CareDx
CDNA
About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Employees: 650
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
152% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $862K
5% more capital invested
Capital invested by funds: $995M [Q1] → $1.05B (+$50.9M) [Q2]
6% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 70
3.78% less ownership
Funds ownership: 101.07% [Q1] → 97.29% (-3.78%) [Q2]
11% less funds holding
Funds holding: 218 [Q1] → 194 (-24) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 46
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
BTIG
Mark Massaro
|
$22
|
Buy
Reiterated
|
12 Sep 2025 |
|
Wells Fargo
Brandon Couillard
|
$14
|
Equal-Weight
Maintained
|
8 Aug 2025 |
|
Craig-Hallum
Connor Chamberlain
|
$26
|
Buy
Maintained
|
18 Jul 2025 |
Financial journalist opinion
Based on 3 articles about CDNA published over the past 30 days
